Dr. Makker on Synergy Between Lenvatinib and Pembrolizumab in Endometrial Cancer

Video

In Partnership With:

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib and pembrolizumab in the treatment of patients with endometrial cancer.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib (Lenvima) and pembrolizumab (Keytruda) in the treatment of patients with endometrial cancer. She presented updated phase Ib/2 data at the 2018 ASCO Annual Meeting.

Lenvatinib targets multiple proteins, including VEGF1-3, FGFR1-4, and platelet—derived growth factor receptor (PDGFR)-alpha. All of these, Makker says, are pathways that are known to promote oncogenesis. Lenvatinib and the PD-1 inhibitor pembrolizumab—both in combination and as single agents—have led to positive preclinical data.

Preclinical data suggested that lenvatinib has antitumor activity, as well as an immunomodulatory effect. Updated data indicate that the 2 agents in combination stimulate the interferon gamma pathways and mediate their efficacy that way.

In the renal cell carcinoma space, this combination received a breakthrough therapy designation in January 2018 for the treatment of patients with advanced or metastatic disease.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD